Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | Yet another biotech is facing a delay from the Food and Drug ...

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

Researchers genetically reprogrammed mouse nerve cells to reverse cell aging, delaying the onset of ALS symptoms in the animals.

A new brain-computer interface technology can decode a user’s inner monologue, an advance that scientists say can help ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

A Jacksonville woman's experience caring for her husband with ALS has formed a foundation to help other families fighting ...

Medically reviewed by Nicholas R. Metrus, MD Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) are both diseases that affect your central nervous system ...

Developing approved therapies for ALS has been painfully slow, as evidenced by the failure of more than 95 per cent of ALS ...

Home NICE Guidance Conditions and diseases Neurological conditions Motor neurone disease Amyotrophic lateral sclerosis - SAR443820 [ID6386] In development [GID-TA11476] Expected publication date: TBC ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic Lateral Sclerosis or ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS typically causes muscle atrophy, difficulty in breathing ...